image credit: Freepik

FDA Approves Flu Treatment for Preventative Use After Exposure

November 24, 2020

Via: BioSpace

Genentech’s influenza treatment Xofluza® (baloxavir marboxil) has been granted approval by the U.S. Food and Drug Administration for use in people 12 years and older, making it the first single-dose post-exposure prophylaxis strategy approved by the agency.

Xofluza, a first-in-class, single-dose oral medicine, has proven itself effective against several influenza viruses. The drug is the first in a class of antivirals that has been shown to inhibit the cap-dependent endonuclease protein, an essential component of viral replication. Non-clinical, in vitro studies have observed the medicine’s activity against oseltamivir-resistant strains and avian strains, including H7N9 and H5N1.

Read More on BioSpace